FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека пептидов

Selank

TP-7 / Selanc

Cognitive & Neuro

Selank is a synthetic heptapeptide anxiolytic developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for enhanced stability. It is approved in Russia and Ukraine as a prescription anxiolytic and nootropic medication, representing a novel class of non-benzodiazepine anxiolytics. Selank modulates GABA, serotonin, dopamine, and norepinephrine systems while simultaneously enhancing immune function through its tuftsin backbone.

Механизм действия

Synthetic heptapeptide analog of endogenous tuftsin with a Pro-Gly-Pro stabilizing sequence. Modulates IL-6, BDNF, and enkephalin expression. Anxiolytic effects mediated through GABAergic modulation without sedation or dependence. Enhances memory consolidation.

Протоколы исследований

Только для исследовательских целей. Не медицинская консультация.

Research protocols use 250-500mcg intranasally 2-3 times daily. Subcutaneous protocols use 250-750mcg daily. Typical cycles are 2-4 weeks. Russian approved protocol: 0.15% nasal drops, 2-3 drops per nostril 3 times daily.

Примечания к исследованиям

Clinical Research Status

Selank is approved in Russia as a nasal spray (0.15% solution) for generalized anxiety disorder and neurasthenia, with regulatory approval obtained in 2009 after extensive clinical trials. It has not entered FDA clinical trials and remains unavailable as an approved medication in the United States or European Union. Russian clinical trials involving over 300 patients demonstrated anxiolytic efficacy comparable to medazepam (a benzodiazepine) without sedation or cognitive impairment. Ongoing research explores applications in PTSD, adjustment disorders, and cognitive enhancement in healthy individuals.

Key Published Findings

A 2008 study in the Bulletin of Experimental Biology and Medicine demonstrated Selank's ability to increase BDNF mRNA expression in the hippocampus by 50% within 24 hours. Research published in Behavioural Brain Research showed dose-dependent anxiolytic effects in the elevated plus-maze model without affecting locomotor activity. Selank has been shown to modulate the expression of 36 genes related to inflammatory and immune responses, including IL-6, according to a 2009 genomics study. Cognitive enhancement studies showed improved memory consolidation and information retrieval in both impaired and healthy subjects.

Safety Profile

Clinical trials and post-marketing surveillance in Russia report no significant adverse effects, sedation, tolerance, or withdrawal symptoms even after prolonged use. Unlike benzodiazepines, Selank does not impair psychomotor function, cause addiction, or produce rebound anxiety upon discontinuation. No LD50 could be established in animal studies as even extreme doses (500x therapeutic) produced no lethal effects. The peptide's short half-life (minutes) and physiologic degradation pathway via aminopeptidases contributes to its favorable safety profile.

Drug Interactions & Contraindications

No significant drug interactions have been identified in published clinical literature, though formal interaction studies are limited in scope. Theoretically, concurrent use with GABAergic drugs (benzodiazepines, barbiturates) may produce additive effects, warranting dose monitoring. Patients with active autoimmune conditions should use caution given Selank's immunomodulatory properties through the tuftsin pathway. Not recommended during pregnancy or lactation due to insufficient safety data in these populations.

Comparison to Related Compounds

Compared to Semax (the other major Russian regulatory peptide), Selank is primarily anxiolytic while Semax is primarily neuroprotective and stimulating; they are frequently combined in clinical practice. Unlike benzodiazepines, Selank does not produce sedation, tolerance, dependence, or cognitive impairment, though its anxiolytic potency may be lower for acute panic. Relative to buspirone (a 5-HT1A partial agonist anxiolytic), Selank has a faster onset of action and additional immunomodulatory benefits. The tuftsin backbone provides immune-enhancing properties absent from all conventional anxiolytics.

Community Observations

Users typically administer Selank intranasally at 200-400 mcg per nostril, 2-3 times daily, reporting onset of anxiolytic effects within 5-15 minutes. Many describe the subjective experience as a calm mental clarity without sedation or emotional blunting, distinct from the heaviness of benzodiazepines. Stacking with Semax is extremely common in the nootropics community, with reported synergy for focused, anxiety-free cognitive performance. Some users report enhanced effects when cycled (3 weeks on, 1 week off) though clinical data does not mandate cycling.

Половая жизнь

~2-3 minutes (intranasal effects last 3-4 hours)

Реконституция

Bacteriostatic water (BAC) for SubQ; saline for nasal

Хранение

Лиофилизированный

Refrigerate 2-8C up to 12 months.

Реконститутированный

Refrigerate 2-8C. Use within 14 days.

Юридический статус США

Research chemical (approved in Russia)

Также известен как

TP-7Selanc

Часто задаваемые вопросы

Что такое Selank?

Selank is a synthetic heptapeptide anxiolytic developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for enhanced stability. It is approved in Russia and Ukraine as a prescription anxiolytic and nootropic medication, representing a novel class of non-benzodiazepine anxiolytics. Selank modulates GABA, serotonin, dopamine, and norepinephrine systems while simultaneously enhancing immune function through its tuftsin backbone.

Как действует Selank?

Synthetic heptapeptide analog of endogenous tuftsin with a Pro-Gly-Pro stabilizing sequence. Modulates IL-6, BDNF, and enkephalin expression. Anxiolytic effects mediated through GABAergic modulation without sedation or dependence. Enhances memory consolidation.

Каков регуляторный статус Selank в США?

Research chemical (approved in Russia)

Каков период полувыведения Selank?

~2-3 minutes (intranasal effects last 3-4 hours)

Как ещё называют Selank?

TP-7, Selanc

Peptide Contacts предоставляет исследовательские сводки только для информационных целей. Мы не хостим, распространяем или одобряем документацию поставщиков. Все сертификаты анализа, GMP-сертификаты и коммуникации с поставщиками должны быть запрослены и проверены непосредственно покупателем. Ничто на этом платформе не является юридическим, медицинским или профессиональным советом. Пользователи самостоятельно отвечают за проверку квалификаций поставщиков и обеспечение соответствия всем применимым местным, штатным и федеральным законам перед покупкой любых исследовательских химикатов. Использование этой платформы означает принятие полной личной ответственности.

Прочитать полное заявление о неприкосновенности